Zeno (zenocutuzumab, or MCLA-128) is being developed for the potential treatment of NRG1 fusion (NRG1+) lung, pancreas and other cancers. The eNRGy trial, a phase 1/2 clinical trial is an ongoing open-label, multicenter trial enrolling patients with NRG1+ solid tumors. The FDA has accepted for review a Biologics License Application for Zeno for the treatment of NRG1+ non-small cell lung and pancreatic cancer (PDUFA date Feb. 4, 2025).
